These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 12451478

  • 1. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 2. Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
    Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.
    Radiat Res; 2007 Jul; 168(1):65-71. PubMed ID: 17722994
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
    Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.
    J Exp Ther Oncol; 2002 Jul; 2(5):298-305. PubMed ID: 12416033
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD.
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):291-8. PubMed ID: 12357303
    [Abstract] [Full Text] [Related]

  • 5. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
    Papadopoulou MV, Bloomer WD, Hollingshead MG.
    Anticancer Res; 2005 Oct; 25(3B):1865-9. PubMed ID: 16158918
    [Abstract] [Full Text] [Related]

  • 6. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Oct; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005 Oct; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 8. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK.
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
    Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S.
    Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
    [Abstract] [Full Text] [Related]

  • 10. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD.
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [Abstract] [Full Text] [Related]

  • 11. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Sep; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 12. Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.
    Papadopoulou MV, Bloomer WD, Torti VR, Page JG.
    Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):497-504. PubMed ID: 20074267
    [Abstract] [Full Text] [Related]

  • 13. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [Abstract] [Full Text] [Related]

  • 14. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 15. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 16. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
    Yuan X, Tabassi K, Williams JA.
    Radiat Oncol Investig; 1999 May 15; 7(4):218-30. PubMed ID: 10492162
    [Abstract] [Full Text] [Related]

  • 17. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Ohnishi K, Takahashi A, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Oncol Rep; 2005 Aug 15; 14(2):393-400. PubMed ID: 16012721
    [Abstract] [Full Text] [Related]

  • 18. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

  • 19. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
    Rose WC.
    J Natl Cancer Inst Monogr; 1993 Jul 15; (15):47-53. PubMed ID: 7912529
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul 15; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.